Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Humanigen, inc. save search
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
Published: 2022-01-10 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: -1.4%
phase 3 fda potential
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
Published: 2021-09-29 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.33%
H: 5.54%
C: -0.81%
presentation results lenzilumab phase 3
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients
Published: 2021-05-05 (Crawled : 17:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -1.0%
H: 12.15%
C: 6.49%
covid results lenzilumab phase 3
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2021-04-09 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.53%
H: 2.41%
C: 1.41%
positive results phase 1 positive results phase 3 phase 2 glioblastoma
Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 57.11%
H: 32.85%
C: -1.68%
covid results topline lenzilumab phase 3 conference
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Published: 2021-03-29 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 57.11%
H: 32.85%
C: -1.68%
covid positive results topline phase 3 lenzilumab
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
Published: 2021-01-29 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 2.46%
H: 3.73%
C: -4.32%
covid phase 3 lenzilumab enroll covid-19
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Published: 2021-01-25 (Crawled : 18:00) - biospace.com/
EBS | News | $2.18 -4.8% 3.21% 750K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.7%
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.71%
H: 1.32%
C: -2.74%
covid contract phase 3 merge lenzilumab
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -0.26%
H: 26.97%
C: 24.14%
phase 3 phase 1 phase 2 enroll glioblastoma
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.